文献速递妇科

卵巢癌患者PARP抑制剂治疗依从性研究

Adherence to PARP inhibitor therapy among women with ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2021-09-09

该研究利用MarketScan数据库评估2008至2017年间启动PARP抑制剂治疗的卵巢癌患者依从性,以≥80%覆盖天数比例(PDC)定义依从。在151例符合纳入标准的患者中,26.5%依从性不佳,非依从者更可能使用尼拉帕利且治疗时间更长。

要点

  • 约四分之一卵巢癌患者PARP抑制剂依从性欠佳(PDC<80%)。
  • 非依从患者更常见使用尼拉帕利且治疗持续时间更长。
  • 年龄、合并症、保险计划及起始年份与依从性无显著关联。

核心结论

  • 基于人群的研究发现约四分之一卵巢癌患者对PARP抑制剂治疗依从性欠佳。

主要发现

  • 从诊断到启动治疗的中位时间为33个月。
  • 总体40例(26.5%)基于PDC<80%判定为非依从。
  • 非依从患者更可能接受尼拉帕利且治疗持续时间更长(p<0.05)。
  • 年龄、合并症、保险计划或PARP抑制剂启动年份对非依从无显著影响。
  • 敏感性分析中非依从率范围为11.3%至41.1%;考虑剂量调整时21.2%患者为非依从。

关键数值与推荐

  • 主要结局依从定义为覆盖天数比例(PDC)≥80%。
  • 次要结局使用药物持有率(MPR)评估依从性。

临床怎么用

  • 临床应关注PARP抑制剂治疗依从性,尤其使用尼拉帕利及治疗时间较长的患者。

局限性

  • 样本量较小(151例),可能限制统计效能与结果外推。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The objective of this study was to evaluate medical adherence for patients with ovarian cancer who initiated treatment with a PARP inhibitor therapy, and to identify factors associated with nonadherence. METHODS: We used the MarketScan Database to identify ovarian cancer patients who initiated PARP inhibitor therapy between January 1, 2008 and December 31, 2017. The primary outcome was adherence defined as ≥ 80% proportion of days covered (PDC). A secondary outcome included adherence assessed using the medication possession ratio (MPR). Multivariable logistic regression analysis was performed to assess relation between PDC and explanatory variables. Sensitivity analysis was performed to evaluate impact of dose-adjustments and toxicity-related delays on adherence. RESULTS: Among 170,976 patients diagnosed with ovarian cancer, 151 patients met inclusion criteria. The median time from diagnosis to initiating therapy was 33 months. Overall, 40 (26.5%) were non-adherent based on a PDC less than 80%. Non-adherent patients were more likely to receive niraparib and have a longer duration of therapy (p < 0.05). We found no significant impact of age, comorbidities, insurance plan, or year of PARP inhibitor initiation on non-adherence. In a sensitivity analysis to assess different definition of adherence, non-adherence ranged from 11.3% to 41.1%. When accounting for possible dose-adjustments, 21.2% of patients were non-adherent. CONCLUSION: This population based study of ovarian cancer patients found that a quarter of patients may be sub-optimally adherent to PARP inhibitor therapy. Future research should focus on identification of patients at risk for nonadherence and interventions to lower nonadherence among these patients.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Moss HA, Chen L, Hershman DL, et al. Adherence to PARP inhibitor therapy among women with ovarian cancer. Gynecol Oncol. 2021. PMID: 34509297. doi:10.1016/j.ygyno.2021.08.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。